Literature DB >> 18514931

Impact of myocardial function on cystatin C measurements in chronic systolic heart failure.

W H Wilson Tang1, Frederick Van Lente, Kevin Shrestha, Richard W Troughton, Gary S Francis, Wilson Tong, Maureen G Martin, Allen G Borowski, Sue Jasper, Randall C Starling, Allan L Klein.   

Abstract

BACKGROUND: The influence of myocardial function on plasma levels of cystatin C (CysC), a sensitive marker of renal function, in chronic systolic heart failure (HF) has not been well established.
METHODS: We prospectively identified 139 subjects with stable, chronic HF (left ventricular ejection fraction < or = 35%) and measured plasma levels of CysC. We prospectively tracked patients' long-term adverse clinical outcomes (death, cardiac transplantation, and HF hospitalizations).
RESULTS: Plasma levels of CysC were elevated in 41% of patients with preserved renal function and directly correlated with N-terminal prohormone brain natriuretic peptide (r = 0.57, P < .0001). There was a significant association between CysC and mitral E/septal E' ratio (r = 0.34, P < .001), right ventricular systolic dysfunction severity (r = 0.30, P < .001), and mitral regurgitation severity (r = 0.31, P < .001), but not left ventricular ejection fraction. At the cutoff of 1.23 mg/dL, CysC remains a significant independent risk factor for adverse clinical outcomes (hazard ratio 1.88, 95% confidence interval 1.15-3.09, P = .012) after adjusting for estimated glomerular filtration rate, left ventricular ejection fraction, and E/septal E'.
CONCLUSION: CysC is associated with more advanced left ventricular diastolic dysfunction and right ventricular systolic dysfunction and remains an independent predictor of long-term prognosis in chronic systolic HF after adjusting for myocardial factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514931     DOI: 10.1016/j.cardfail.2008.01.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  21 in total

1.  Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events.

Authors:  Matthias Dupont; Yuping Wu; Stanley L Hazen; W H Wilson Tang
Journal:  Circ Heart Fail       Date:  2012-08-16       Impact factor: 8.790

2.  Cystatin C and galectin-3 as therapeutic targets in heart failure.

Authors:  Christos Zivlas; Filippos Triposkiadis; Stelios Psarras; Gregory Giamouzis; Ioannis Skoularigis; Stavros Chryssanthopoulos; Alkistis Kapelouzou; Steve Ramcharitar; Edward Barnes; Evangelos Papasteriadis; Dennis Cokkinos
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-31

3.  Cystatin C, creatinine, and albuminuria: bringing risk into 3 dimensions.

Authors:  Joseph A Abdelmalek; Dena E Rifkin
Journal:  Am J Kidney Dis       Date:  2012-08       Impact factor: 8.860

4.  Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation.

Authors:  Lifang Xie; Jerome Terrand; Beibei Xu; George Tsaprailis; Jean Boyer; Qin M Chen
Journal:  Cardiovasc Res       Date:  2010-05-20       Impact factor: 10.787

5.  Impact of cystatin C levels on infarct size and hemorrhage volume in acute cerebral stroke.

Authors:  Dongfang Xiao; Hailong Liu; Hong Zhang; Yumin Luo
Journal:  J Neurol       Date:  2012-02-18       Impact factor: 4.849

6.  Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

Authors:  W H Wilson Tang; Kevin Shrestha; Zhili Shao; Allen G Borowski; Richard W Troughton; James D Thomas; Allan L Klein
Journal:  Am J Cardiol       Date:  2011-05-19       Impact factor: 2.778

7.  Prognostic implications of relative hypochromia in ambulatory patients with chronic systolic heart failure.

Authors:  Cesar Simbaqueba; Kevin Shrestha; Maria Patarroyo; Richard W Troughton; Allen G Borowski; Allan L Klein; W H Wilson Tang
Journal:  Congest Heart Fail       Date:  2012-12-19

Review 8.  Novel renal biomarkers to assess cardiorenal syndrome.

Authors:  Meredith A Brisco; Jeffrey M Testani
Journal:  Curr Heart Fail Rep       Date:  2014-12

9.  Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure.

Authors:  W H Wilson Tang; Zeneng Wang; Kevin Shrestha; Allen G Borowski; Yuping Wu; Richard W Troughton; Allan L Klein; Stanley L Hazen
Journal:  J Card Fail       Date:  2014-11-20       Impact factor: 5.712

10.  Differential prognostic utility of NTproBNP and Cystatin C in patients with acute exacerbation of chronic pulmonary disease.

Authors:  Juan I Pérez-Calvo; Marta Sánchez-Marteles; Francisco-José Ruiz-Ruiz; José-Luis Morales-Rull; José-Antonio Nieto-Rodríguez
Journal:  JRSM Short Rep       Date:  2010-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.